82例子宫内膜癌错配修复蛋白表达与临床病理特征的关系

doi:10.3969/j.issn.1000-8535.2023.12.007

摘要/Abstract

摘要： 目的探讨子宫内膜癌构成及临床病理特征。方法以南平市第一医院2020年1月—2022年6月期间收治的82例子宫内膜癌患者为研究对象,收集其临床资料,通过免疫组织化学染色法检测4种错配修复蛋白表达,并分析错配修复蛋白表达与临床病理特征的关系。结果 82例患者中,70例（85.37%）为子宫内膜样癌,病理组织学类型以G1级30例（42.86%）为主,其他类型较为少见。错配修复蛋白表达总缺失率为35.71%,其中MUTL同源物1（MLH1）单独缺失率为2.86%,错配修复蛋白2抗体（MSH2）为4.29%,错配修复蛋白6抗体（MSH6）为14.29%,肿瘤错配修复基因PMS2抗体（PMS2）为14.29%;错配修复表达缺失（dMMR）组患者年龄50岁以上、伴脉管侵犯和淋巴结转移、组织学G3级和FIGO分期Ⅲ期占比高于错配修复表达正常（pMMR）组患者（P<0.05）;MSH6蛋白表达缺失易发生在年龄50岁以上、有家族相关疾病史的患者（P<0.05）;PMS2蛋白表达缺失易发生在组织学G2级、FIGO分期Ⅲ期、妊娠1次及以上、脉管内癌栓和淋巴结转移的患者（P<0.05）。结论子宫内膜癌错配修复蛋白表达与其部分临床病理特征存在密切关联,可为患者后续治疗提供有价值的指导。

关键词: 子宫内膜癌, 临床病理特征, 免疫组织化学染色, 错配修复

Abstract: Objective To investigate the composition and clinicopathological features of endometrial carcinoma．Methods A total of 82 cases of endometrial carcinoma patients admitted to the First Hospital of Nanping City from January 2020 to June 2022 were studied．Epidemiological data were collected,and the expression of 4 mismatch repair proteins were detected by immunohistochemical staining,and their relationship with clinicopathological features was analyzed．Results Among 82 patients,70 cases（85.37%）were endometrioid carcinoma,and 30 cases（42.86%）were mainly G1 grade,other types were rare．The total deletion rate of mismatch repair proteins expression was 35.71%,in which MLH1 alone was 2.86%,MSH2 was 4.29%,MSH6 was14.29% and PMS2 was14.29%．The proportions of dMMR patients over 50 years old,with vascular invasion and lymph node metastasis,G3 grade histology and FIGO stage Ⅲ were significantly higher than those of the pMMR group（P<0.05）．The loss of MSH6 protein expression was more likely to occur in patients over 50 years old with a family history of related diseases（P<0.05）．The deletion of PMS2 protein expression was more likely to occur in patients with histological G2 grade,FIGO stage III,pregnancy of once or more and intravascular cancer thrombin and lymph node metastasis（P<0.05）．Conclusions The expression of mismatch repair proteins in endometrial carcinoma is closely related to some clinicopathological features,which provides valuable guidance for follow-up treatment．

Key words: endometrial carcinoma, clinicopathological features, immunohistochemical staining, mismatch repair

吴克姣, 陈明光, 刘继英. 82例子宫内膜癌错配修复蛋白表达与临床病理特征的关系[J]. 广州医药, 2023, 54(12): 44-48.

WU Kejiao, CHEN Mingguang, LIU Jiying. The structure and clinicopathological features of endometrial carcinoma in 82 cases[J]. Guangzhou Medical Journal, 2023, 54(12): 44-48.

参考文献

[1] 林泽宇,宁莹,初慧君,等.子宫内膜小细胞癌6例临床特点及病理分析[J].现代妇产科进展,2023,32(3):221-223,227.
[2] 任润玲,闫志风,李明霞,等.特殊病理类型子宫内膜癌分子分型特征及其临床应用的研究进展[J].解放军医学院学报,2023,44(3):287-292.
[3] 任文彬,崔向荣,张三元.子宫内膜癌的分子病理分型及其研究进展[J].国际妇产科学杂志,2022,49(3):272-277.
[4] 张敏,陈慧,杨玉婵,等.卵巢子宫内膜样癌与高级别浆液性癌临床及MRI特征的对照分析[J].中国中西医结合影像学杂志,2023,21(1):39-43,61.
[5] 陈瑶,李阳,吕卫国.错配修复通路缺陷型子宫内膜癌的临床病理特点及其治疗的研究进展[J].中华医学杂志,2023,103(20):1580-1584.
[6] 陈贝贝,李君,李力,等.Lynch综合征相关子宫内膜癌老年患者的临床特征及家系MSH2基因变异分析[J].中华老年医学杂志,2023,42(2):202-205.
[7] 宋晓霞,刘玉玲,张琦.子宫内膜癌中LncRNA FAM83H-AS1的表达以及与患者临床病理特征和预后的关系[J].河南大学学报(医学版),2023,42(2):135-140.
[8] 陈利平,滕芸,张娟.子宫内膜癌患者血清结缔组织生长因子、乙二醛酶Ⅰ、丙酮酸激酶M2水平变化及与临床病理特征的关系[J].中国医师进修杂志,2023(2):180-184.
[9] 杨珈苹,苏翠滢,贾英.子宫内膜异位症相关性卵巢癌的临床特征及预后分析[J].重庆医学,2023,52(7):1015-1020.
[10] 李莉,吴晋蓉,韩梅,等.9例子宫内膜和卵巢同步癌的临床病理特征[J].临床肿瘤学杂志,2023,28(1):64-69.
[11] 汪积瀛,王若白,李秀明.子宫内膜癌临床病理特征与盆腔淋巴结转移的影响因素分析[J].系统医学,2023,8(2):37-40.
[12] 陈曦,杨永秀.微卫星不稳定型子宫内膜癌的临床特点和治疗[J].国际生殖健康／计划生育杂志,2023,42(1):77-82.
[13] 孙丽丽,刘格丹,贾楠,等.不同分子分型的子宫内膜癌临床病理特征分析[J].肿瘤预防与治疗,2022,35(5):435-441.
[14] 李文琪,申彦.子宫内膜癌分子分型与临床病理特征分析[J].中华病理学杂志,2022,51(10):993-999.
[15] 祁晓莉,谢丽梦,张立英,等.子宫内膜癌KRAS的分子检测及临床病理特征分析[J].临床和实验医学杂志,2022,21(16):1744-1748.
[16] 刘艳梅,杨丽丽,岳娜,等.新疆地区2718例子宫内膜癌构成及临床病理特征[J].临床与实验病理学杂志,2023,39(5):544-550.